Zurcher Kantonalbank Zurich Cantonalbank Buys 27,436 Shares of Novavax, Inc. (NASDAQ:NVAX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 45.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 87,739 shares of the biopharmaceutical company’s stock after buying an additional 27,436 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.07% of Novavax worth $421,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of NVAX. Commonwealth Equity Services LLC lifted its stake in shares of Novavax by 14.6% during the third quarter. Commonwealth Equity Services LLC now owns 17,307 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 2,201 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in Novavax during the 3rd quarter valued at about $212,000. Raymond James & Associates bought a new position in shares of Novavax in the 3rd quarter valued at about $1,021,000. Raymond James Financial Services Advisors Inc. bought a new position in Novavax in the third quarter valued at approximately $76,000. Finally, Bank of New York Mellon Corp grew its holdings in Novavax by 3.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 364,532 shares of the biopharmaceutical company’s stock worth $2,639,000 after acquiring an additional 13,326 shares during the period. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Price Performance

Shares of NVAX stock opened at $4.93 on Friday. The stock has a 50-day moving average of $4.71 and a 200-day moving average of $5.03. Novavax, Inc. has a one year low of $3.53 and a one year high of $11.36. The stock has a market cap of $692.17 million, a PE ratio of -0.89 and a beta of 1.63.

Novavax (NASDAQ:NVAX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.95). The business had revenue of $291.34 million for the quarter, compared to analysts’ expectations of $310.96 million. During the same period in the previous year, the firm earned ($2.28) earnings per share. The business’s quarterly revenue was down 18.5% on a year-over-year basis. As a group, research analysts anticipate that Novavax, Inc. will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright cut their price target on Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.